Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics.

Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics.

An In Vitro Comparative Immunogenicity Assessment (IVCIA) assay was evaluated as a tool for predicting the potential relative immunogenicity of biotherapeutic attributes. Peripheral blood mononuclear cells from up to 50 healthy naïve human donors were monitored up to 8 days for T-cell proliferation,...

Full description

Bibliographic Details
Main Authors: Marisa K Joubert, Meghana Deshpande, Jane Yang, Helen Reynolds, Christine Bryson, Mark Fogg, Matthew P Baker, Jonathan Herskovitz, Theresa J Goletz, Lei Zhou, Michael Moxness, Gregory C Flynn, Linda O Narhi, Vibha Jawa
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4975389?pdf=render

Internet

http://europepmc.org/articles/PMC4975389?pdf=render

Similar Items